Plain-English translation of NCT05699005 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
When your heart fails severely, doctors may place you on a special machine called VA-ECMO that does your heart's pumping job while it recovers. These machines often require many blood transfusions because they damage red blood cells and patients bleed more easily. This trial is testing whether a smarter way to decide when you need transfusions—by measuring how much oxygen your body is actually receiving—works better than the current standard approach of giving transfusions based on a fixed blood count number.
Patients on heart support machines currently receive a lot of blood transfusions, which can cause serious complications and may actually worsen outcomes. There's no agreed-upon best way to decide when transfusions are truly necessary, so doctors need better guidance tailored to each patient's unique situation.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two blood transfusion strategies while you're on the heart support machine. In the standard approach, you'll receive transfusions when your hemoglobin (a protein that carries oxygen in blood) drops below 9 g/dL. In the personalized approach, doctors will give transfusions only when a measurement called ScVO2—which reflects how much oxygen your body's tissues are receiving—drops below 65%, and only after checking that your breathing, fluid levels, machine settings, fever, anxiety, and pain are all optimized. Throughout your treatment, doctors will monitor your condition and compare outcomes between the two strategies.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
France